The global dermatology diagnostic devices and therapeutics market size accounted for USD 14.84 billion in 2024, grew to USD 15.9 billion in 2025 and is predicted to surpass around USD 29.47 billion by 2034, representing a healthy CAGR of 7.10% between 2024 and 2034. The North America dermatology diagnostic devices and therapeutics market size is calculated at USD 6.08 billion in 2024 and is expected to grow at a fastest CAGR of 7.22% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dermatology Diagnostic Devices And Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dermatology Diagnostic Devices And Therapeutics Market, by Diagnostic Devices, 2024-2034
8.1.1 Dermatoscopes
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Microscopes and Trichoscopes
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Imaging Equipment
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Dermatology Diagnostic Devices And Therapeutics Market, by Application Class, 2024-2034
9.1.1. Diagnostic Devices
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Treatment Devices
10.1. Dermatology Diagnostic Devices And Therapeutics Market, by End Use, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
11.1. North America
11.1.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.1.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.1.3. Market Revenue and Forecast, by End Use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.2.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.2.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.3.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.3.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Diagnostic Devices (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application Class (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End Use (2021-2034)
12.1. Canfield Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis International AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Valeant Pharmaceuticals International, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. gfa-Gevaert N.V.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Galderma S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Michelson Diagnostics Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cutera, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Astellas Pharma, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Genentech
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GlaxoSmithKline plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample